Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.
Several new studies presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI) underscore the complex ways that HIV risk and treatment adherence manifest among women of childbearing age.
Study highlights the need for PrEP and other HIV prevention strategies for pregnant women and new mothers in high-prevalence settings.
Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.
No increase in poor birth outcomes with PrEP used throughout pregnancy in the Partners Demonstration project.
While antiretroviral therapy in pregnancy reduced vertical transmission, it also increased the frequency of several adverse birth outcomes compared with antenatal zidovudine (AZT) alone.
HIV-positive pregnant women receiving lopinavir/ritonavir-based regimens were at higher risk of preterm delivery compared with those on NNRTI-based regimens.
Among pregnant women with HIV in the PROMISE trial, use of TDF/FTC/LPV/r was not associated with increased risk of adverse infant birth outcomes when compared to AZT/3TC/LPV/r or TDF/FTC/ATV/r.
Researchers compared birth outcomes with in-utero exposure from conception to the five most common antiretroviral therapy regimens used in Botswana.
Tenofovir DF-containing ART decreases bone mineral density in HIV-positive, breast-feeding women, according to findings presented at the 8th International Workshop on HIV Paediatrics.